Abstract 6864: Reduced Dose versus Full Dose Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta Analysis
Abstract
Background: Patients with venous thromboembolism (VTE) who complete initial anticoagulation often require extended therapy to prevent recurrence, but this must be balanced against bleeding risks. While reduced-dose direct oral anticoagulants (DOACs) are increasingly used, their comparative efficacy and safety versus full-dose DOACs across diverse populations including cancer-associated thrombosis remains debated. Methods: We searched PubMed, EMBASE, and Cochrane CENTRAL for randomized controlled trials (RCTs) comparing reduced-dose DOACs (apixaban 2.5 mg BID or rivaroxaban 10 mg OD) against full-dose DOACs for extended VTE treatment (≥6 months). The primary efficacy outcome was recurrent VTE, and the primary safety outcome was major bleeding. Secondary outcomes included clinically relevant non-major bleeding (CRNMB) and all-cause mortality. We pooled risk ratios (RRs) with 95% confidence intervals (CIs) using a DerSimonian-Laird random-effects model. A pre-specified sensitivity analysis was conducted by adding the recently published HI-PRO trial, which compared reduced-dose apixaban to placebo. Results: The primary analysis included 5 RCTs (AMPLIFY-EXT, EINSTEIN CHOICE, RENOVE, EVE, API-CAT) comprising 8,781 patients. Compared to full-dose DOACs, reduced-dose DOACs demonstrated comparable efficacy in preventing recurrent VTE (RR 0.91, 95% CI 0.66-1.26; I 2 =0.0%) and comparable all-cause mortality (RR 0.89, 95% CI 0.75-1.06; I 2 =0.0%). For safety, reduced-dose DOACs showed a trend toward lower major bleeding (RR 0.72, 95% CI 0.50-1.04; I 2 =0.0%) and significantly reduced CRNMB (RR 0.72, 95% CI 0.61-0.85; p<0.001; I 2 =0.0%). In the sensitivity analysis incorporating the placebo-controlled HI-PRO trial (total 6 RCTs, n=9,381), the pooled RR for recurrent VTE shifted to 0.71 (95% CI 0.41-1.21), but introduced substantial heterogeneity (I 2 =64.7%), driven entirely by the placebo comparator in HI-PRO (RR 0.13, 95% CI 0.05-0.37). Mortality remained consistent in the 6-study analysis (RR 0.88, 95% CI 0.75-1.05; I 2 =0.0%). Conclusion: For the extended treatment of VTE, reduced-dose DOACs are as effective as full-dose DOACs in preventing recurrence and mortality, while significantly reducing the risk of clinically relevant non-major bleeding by 28%. The inclusion of placebo-controlled data introduces significant heterogeneity, highlighting that reduced-dose DOACs are vastly superior to placebo for efficacy, but non-inferior to full-dose DOACs with an optimized safety profile. These findings support the routine use of reduced-dose DOACs for extended VTE secondary prevention across broad patient populations.